The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients (Q38970636)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients (English)

1 reference

Europe PubMed Central

8 September 2017

author name string

Moutaz Derbala

1

1 reference

Europe PubMed Central

8 September 2017

Nasser M Rizk

2

1 reference

Europe PubMed Central

8 September 2017

Nasser M Rizk

3

1 reference

Europe PubMed Central

8 September 2017

Saad Al-Kaabi

4

1 reference

Europe PubMed Central

8 September 2017

Anil John

5

1 reference

Europe PubMed Central

8 September 2017

Manik Sharma

6

1 reference

Europe PubMed Central

8 September 2017

Nazeeh El-dweik

7

1 reference

Europe PubMed Central

8 September 2017

Rafie Yakoob

8

1 reference

Europe PubMed Central

8 September 2017

Fuad Pasic

9

1 reference

Europe PubMed Central

8 September 2017

Muneera Almohanadi

10

1 reference

Europe PubMed Central

8 September 2017

Khalid Alejji

11

1 reference

Europe PubMed Central

8 September 2017

Abdulatif Abdelmola

12

1 reference

Europe PubMed Central

8 September 2017

Mohamed Butt

13

1 reference

Europe PubMed Central

8 September 2017

language of work or name

0 references

publication date

16 July 2013

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

444

1 reference

Europe PubMed Central

8 September 2017

1-2

1 reference

Europe PubMed Central

8 September 2017

292-300

1 reference

Europe PubMed Central

8 September 2017

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

IL28B and the control of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Chemokine antagonism in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleuk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Hepatitis C genotype 4: What we know and what we don't yet know.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.06.025

7 January 2021

Identifiers

10.1016/J.VIROL.2013.06.025

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38970636&oldid=1988137455"